Insulin Board

The FDA has approved the new long acting basal insulin, Toujeo. The insulin, which has carried the working name U300 has been developed by Sanofi, the firm that produces the currently most prescribed insulin Lantus.

Long acting insulin

Toujeo shares the active ingredient, insulin glargine, as Lantus but its formulation gives it a flatter profile than Lantus enabling it to reduce episodes of hypoglycaemia. Toujeo is taken once daily and is available for people with type 1 and type 2 diabetes.

Lantus patent expiring

Sanofi’s patent for Lantus is due to expire shortly. When the patent expires, it will mean that other companies will be able to produce and sell the same, or similar, formulations as Lantus. This will likely result in a large drop in price for the drug.

Sanofi are keen to switch people onto Toujeo as this will enable the company to keep up their profits. However, the question will be whether doctors and patients will find enough benefit in Toujeo to justify what is set to be a more expensive medication.

Toujeo reduces night time hypos by 31%

Toujeo’s main advantage over Lantus is its ability to reduce incidence of hypoglycemia and, in particular, instances of nocturnal (night time) hypoglycemia.

In clinical trials of patients with type 2 diabetes, Toujeo usage was associated with a 14% lower rate of hypos at any time of day with a 31% lower rate of specifically nocturnal hypos.